论文部分内容阅读
目的:对比研究瑞舒伐他汀与阿托伐他汀对冠心病患者的降脂疗效,为临床治疗冠心病提供药物治疗方案依据。方法:随机选取江西省泰和县人民医院2015年1月至2016年1月收治的120例冠心病且伴有高脂血症患者,分为对照组和观察组,各60例,对照组给予阿托伐他汀口服药物进行治疗,同法观察组给予瑞舒伐他汀,比较两组患者治疗前与治疗后血脂水平、超敏C–反应蛋白(hs–CRP)水平及空腹血糖(FBG)水平。结果:两组患者治疗后的血脂和hs–CRP水平明显低于未接受治疗前,差异具有统计学意义(P<0.05),而两组患者FBG治疗前后无明显变化,差异无统计学意义(P>0.05);两组患者治疗后,观察组低密度脂蛋白胆固醇(LDL–C)、总胆固醇(TC)及hs–CRP的下降水平明显优于对照组,差异具有统计学意义(P<0.05),两组高密度脂蛋白胆固醇(HDL–C)的升高和三酰甘油(TG)水平的降低变化不明显,差异无统计学意义(P>0.05)。结论:瑞舒伐他汀与阿托伐他汀两种药物均可显著降低冠心病患者的血脂水平,但瑞舒伐他汀的综合治疗效果更优。
Objective: To compare the lipid-lowering efficacy of rosuvastatin and atorvastatin on patients with coronary heart disease and to provide evidence for clinical treatment of coronary heart disease. Methods: 120 patients with coronary heart disease and hyperlipidemia admitted from January 2015 to January 2016 in Taihe People’s Hospital of Jiangxi Province were randomly divided into control group and observation group, with 60 cases in each group. The control group was given A Atorvastatin was given as oral medication, rosuvastatin was given to the same observation group, blood lipid level, high-sensitivity C-reactive protein (hs-CRP) level and fasting blood glucose (FBG) level were compared between the two groups before and after treatment. Results: The levels of serum lipids and hs-CRP after treatment in both groups were significantly lower than those before treatment (P <0.05), but there was no significant difference between the two groups before and after treatment P <0.05). After treatment, the levels of low density lipoprotein cholesterol (LDL-C), total cholesterol (TC) and hs-CRP in the two groups were significantly better than those in the control group, with statistical significance (P < 0.05). There was no significant difference between two groups in HDL-C and triglyceride (TG) (P> 0.05). Conclusion: Both rosuvastatin and atorvastatin can significantly reduce the level of blood lipid in patients with coronary heart disease, but rosuvastatin is more effective in the comprehensive treatment.